The small molecule SMO antagonist LDE225 inhibits downstream Hh signaling in vivo in a CP-CML murine model and in primary CD34+ CP-CML cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.